Van ECK Associates Corp Acquires 4,103 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Van ECK Associates Corp boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 6.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,944 shares of the company’s stock after purchasing an additional 4,103 shares during the quarter. Van ECK Associates Corp owned about 0.08% of CRISPR Therapeutics worth $4,904,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. Blue Trust Inc. bought a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $32,000. Bourgeon Capital Management LLC increased its stake in CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the last quarter. NBC Securities Inc. increased its stake in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after acquiring an additional 438 shares during the last quarter. Principal Securities Inc. bought a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $41,000. Finally, Benjamin F. Edwards & Company Inc. increased its position in shares of CRISPR Therapeutics by 563.0% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 663 shares of the company’s stock valued at $45,000 after purchasing an additional 563 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 2.1 %

Shares of CRSP traded down $1.15 during trading hours on Friday, hitting $52.75. The company had a trading volume of 862,509 shares, compared to its average volume of 1,629,300. The company has a market capitalization of $4.48 billion, a PE ratio of -19.82 and a beta of 1.70. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The company’s fifty day moving average price is $56.59 and its two-hundred day moving average price is $64.26.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $25.53 million. The company’s quarterly revenue was down 99.5% on a year-over-year basis. During the same period last year, the firm posted ($0.67) earnings per share. Analysts forecast that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on CRSP shares. Robert W. Baird boosted their target price on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Needham & Company LLC reissued a “buy” rating and set a $88.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, June 27th. Barclays cut their target price on CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 9th. JMP Securities reissued a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $75.71.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.